Prof. Franco Battista Ennio Folli

University of Milano, Italy

Email: [email protected]

Qualifications

1996 Ph.D., Università di Milano e Padova, Italy

Publications (Selected)

1. Nasini, S., Tidei, S., Barzon, B., De Martin, S., Banzato, M., Folli, F., ... & Comai, S. (2025). ANXIOLYTIC-AND PROCOGNITIVE-LIKE EFFECTS OF A 30-DAY CHRONIC TREATMENT WITH A LOW NON-PSYCHEDELIC DOSE OF PSILOCYBIN IN C57BL/6J MICE. International Journal of Neuropsychopharmacology, 28(Suppl 1), i108.
2. Berra, C., Manfrini, R., Bifari, F., Cipponeri, E., Ghelardi, R., Centofanti, L., ... & Folli, F. (2024). Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE− 2 study. Pharmacological Research, 210, 107517.
3. Pontiroli, A. E., Centofanti, L., Zakaria, A. S., Cerutti, S., Dei Cas, M., Paroni, R., ... & Folli, F. (2024). The triglyceride-glucose index, blood glucose levels, and metabolic syndrome are associated with all-cause mortality in obesity. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 18(10), 103146.
4. Nasr, M. B., Usuelli, V., Dellepiane, S., Seelam, A. J., Fiorentino, T. V., D’Addio, F., ... & Folli, F. (2024). Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule. Cell Metabolism, 36(6), 1302-1319.
5. Folli, F., Centofanti, L., Magnani, S., Tagliabue, E., Bignotto, M., La Sala, L., & Pontiroli, A. E. (2024). Obesity effect on newly diagnosed and recurrent post-ablation atrial fibrillation: A systematic review and meta-analysis. Journal of endocrinological investigation, 47(5), 1051-1066.
6. Folli, F., Pontiroli, A. E., Zakaria, A. S., Centofanti, L., Tagliabue, E., & La Sala, L. (2024). Alanine transferase levels (ALT) and triglyceride-glucose index are risk factors for type 2 diabetes mellitus in obese patients. Acta Diabetologica, 61(4), 435-440.
7. Folli, F., Finzi, G., Manfrini, R., Galli, A., Casiraghi, F., Centofanti, L., ... & Higgins, P. B. (2023). Mechanisms of action of incretin receptor based dual-and tri-agonists in pancreatic islets. American Journal of Physiology-Endocrinology and Metabolism, 325(5), E595-E609.
8. Fava, M., Stahl, S. M., De Martin, S., Mattarei, A., Bettini, E., Folli, F., ... & Manfredi, P. L. (2023). Esmethadone-HCl (REL-1017): a promising rapid antidepressant. European Archives of Psychiatry and Clinical Neuroscience, 273(7), 1463-1476.
9. Shram, M. J., Henningfield, J. E., Apseloff, G., Gorodetzky, C. W., De Martin, S., Folli, F., ... & Pappagallo, M. (2023). The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users. Translational Psychiatry, 13(1), 192.
10. Piccini, S., Favacchio, G., Panico, C., Morenghi, E., Folli, F., Mazziotti, G., ... & Mirani, M. (2023). Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study. Cardiovascular Diabetology, 22(1), 69.
11. Tobar, N., Rocha, G. Z., Santos, A., Guadagnini, D., Assalin, H. B., Folli, F., ... & Saad, M. J. (2023). Metformin acts in the gut and induces gut-liver crosstalk. Proceedings of the National Academy of Sciences, 120(4), e2211933120.
12. Stahl, S. M., De Martin, S., Mattarei, A., Bettini, E., Pani, L., Folli, F., ... & Manfredi, P. L. (2022). Esmethadone (REL-1017) and other uncompetitive NMDAR channel blockers may improve mood disorders via modulation of synaptic kinase-mediated signaling. International Journal of Molecular Sciences, 23(20), 12196.
13. Bifari, F., Pappagallo, M., Bleavins, M., Traversa, S., Folli, F., & Manfredi, P. L. (2022). REL-1017 (esmethadone), a novel NMDAR blocker for the treatment of MDD is not neurotoxic in Sprague-Dawley rats. Frontiers in Pharmacology, 13, 863959.
14. La Sala, L., Tagliabue, E., Vieira, E., Pontiroli, A. E., & Folli, F. (2021). High plasma renin activity associates with obesity-related diabetes and arterial hypertension, and predicts persistent hypertension after bariatric surgery. Cardiovascular Diabetology, 20(1), 118.

Profile Details

WoS ResearcherID: J-2795-2018

https://orcid.org/0000-0001-9824-5222

https://www.unimi.it/en/ugov/person/franco-folli

https://scholar.google.com.hk/citations?user=UriDBz4AAAAJ&hl=zh-CN&oi=sra

https://www.researchgate.net/profile/Franco-Folli